Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

UnitedHealth's OptumRx to pass 100% of drug rebates to clients by 2028, but critics say GPO structure may still hide true ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.

Dr Okafo’s recent publications have focused on analytical strategies for characterising synthetic oligonucleotides and, in 2010, he co-organised an international analytical symposium on characterising ...

SB BIOSCIENCE Inc., Room 120, Venture Building, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea ...

miRNA expression profiles can be used to diagnose a disease state and the deregulated miRNAs contribute to the initiation and development of this disease; The mouse models already developed prove ...

A team of biochemists at the Manchester Institute of Biotechnology has developed an isothermal biocatalytic process that can be used to manufacture therapeutic oligonucleotides in large volumes.

Capital structure is the mix of debt and equity that fund a company's operations. A judicious use of debt and equity is a key indicator of a strong balance sheet. A healthy capital structure that ...

Carboxylic acids have been shown to be good phosphate bioisosteres (Burke and Lee, 2003; Elliott et al., 2012). Yet phosphonic acids could potentially better-replicate cognate TOP1-DNA substrate ...